Zydus Lifesciences Opens Higher, But Slips Into Red

Shares of

opened on a positive note on 19 Feb 2026, gapping up over 1% ahead of a key regulatory development. The company announced it received final approval from the United States Food and Drug Administration for Bosentan tablets for oral suspension (32 mg), used to treat Pulmonary Arterial Hypertension. The product will be manufactured at the group’s SEZ formulation facility in Ahmedabad. However, the early gains faded quickly. By 3:10 PM, the stock was trading in the red amid broader market weakness. Most major sectors remained under pressure, with Nifty Realty (-2.5%) among the top losers, while NIFTYPHARMA traded, down about 0.4%. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.